Work

Does osimertinib treatment discriminate young patients?

Year: 2019

Type: article

Abstract: Osimertinib (AZD9291 or TAGRISSO™) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) developed to overcome T790M-induced resistance, which accounts for approximately 60% of resistant cases after 1 st generation EGFR-TKI treatment. Beyond T790M mutation, osimertinib also selectively and irreversibly inhibits EGFR harboring the common “sensitive” mutations such as 19del and L858R.

Source: Journal of Thoracic Disease

DOI: 10.21037/jtd.2019.08.118

Authors: Cheng Ji, Chongke Zhong, Shi-Yong Sun

Institutions: First Affiliated Hospital of Soochow University, Soochow University, Emory University, Winship Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

Funder: Emory University